One balance. Every market.
Place limit orders on many Seer prediction markets with the same sDAI. It stays in your wallet and moves only when someone takes the other side — on the one market where they do.
Place ordersOpen markets (213)
Will there be at least one significant partnership or collaboration aimed at advancing the development or commercialization of either Metformin or Rapamycin for lifespan extension by the end of 2025?
No Seer odds yet
Seer oddsReading orders…Will Metformin or Rapamycin be designated as a Breakthrough Therapy by the FDA for life extension purposes by the end of 2025?
No Seer odds yet
Seer oddsReading orders…Summer will come 2025?
No Seer odds yet
Seer oddsReading orders…Will the EU invoke the Anti-Coercion Instrument (ACI) before 1 July 2025?
No Seer odds yet
Seer oddsReading orders…
Will the Federal Reserve lower the target Fed Funds rate via an unscheduled meeting before July 1st 2025?
No Seer odds yet
Seer oddsReading orders…Will the Federal Reserve lower the target Fed Funds rate via an unscheduled meeting before July 1st 2025?
No Seer odds yet
Seer oddsReading orders…Will the Federal Reserve lower the target Fed Funds rate via an unscheduled meeting before July 1st 2025?
No Seer odds yet
Seer oddsReading orders…Will Vine be relaunched before July 2025?
No Seer odds yet
Seer oddsReading orders…Test?
No Seer odds yet
Seer oddsReading orders…If research into Rapamycin, Metformin or their combination shows promising longevity benefits, by December 31, 2041, in the context of a large-scale population based observational studies or randomised controlled trials in healthy individuals aged 50 and older, will the group not using either Metformin or Rapamycin while still receiving a stand healthcare will show median lifespan or rate of biological ageing that is not significantly lower than the groups using either or both drugs.
No Seer odds yet
Seer oddsReading orders…Assuming research into individual Rapamycin and Metformin effectiveness shows promise, by December 31, 2041, will a peer reviewed, randomised controlled trial comparing combination therapy (Rapamycin and Metformin) to monotherapy (either Rapamycin or Metformin alone) and placebo in healthy individuals aged 50 and above shows a statistically significant increment in median lifespan or there is a measurable decrement of biological ageing than it earlier was, compared to monotherapy, with results meeting p-value of less than 5% (0.05).
No Seer odds yet
Seer oddsReading orders…By December 31, 2030, will a peer reviewed, randomised controlled trial or a FDA reviewed NDA which indicated longevity for this drug is published in a top tier medical journal confirm that on-label usage of Metformin in healthy individuals aged 50 and above produces a statistically significant increment in median lifespan or there is a measurable decrement of biological ageing than it earlier was, compared to placebo, with results meeting p-value of less than 5% (0.05).
No Seer odds yet
Seer oddsReading orders…
Plain YES/NO Seer markets on Gnosis, collateral sDAI, not yet answered. Odds and liquidity are Seer's own; OddsFlow prices come from open orders.